Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chang An Kang capsule is a traditional Chinese medicine (TCM) developed by Beijing Huaxia Yisheng Innovation Technology for the treatment of chronic ulcerative colitis. It is specifically indicated for patients presenting with the 'Damp-Heat Internal Accumulation' syndrome according to TCM principles. The drug has undergone Phase IIb clinical testing in China to evaluate its safety and efficacy in adults with mild, chronic relapsing ulcerative colitis. As a botanical formulation, it likely functions through multi-target anti-inflammatory and mucosal protective pathways common to herbal treatments for inflammatory bowel disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chang An Kang capsule.